Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 17/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.48 |
| ▸ | MTOR | P42345 | 6/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608346 | 0.90 | PRKDC (0.49) | PRKDCPIK3CAMTOR | |
| SCHEMBL9608318 | 0.86 | ALDH1A1 (0.48) | PRKDCPIK3CAMTORPDE1BPDE4A | |
| SCHEMBL9608313 | 0.73 | PDE1B (0.45) | PDE1B | |
| SCHEMBL13334361 | 0.72 | PDE1B (0.47) | PDE1B | |
| SCHEMBL15943433 | 0.71 | PDE4A (0.39) | PRKDCPIK3CAMTORPDE1BPDE4A | |
| SCHEMBL2612352 | 0.68 | PDE1B (0.43) | PRKDCPIK3CAMTORPDE1BPDE5A | |
| SCHEMBL13334388 | 0.67 | PDE1B (0.39) | PDE1BPDE4A | |
| SCHEMBL2455942 | 0.67 | PDE1B (0.48) | PDE1BPDE5APDE4APDE3BPDE11A | |
| SCHEMBL9608307 | 0.67 | PDE1B (0.48) | PDE1BPDE5APDE4APDE3BPDE11A | |
| SCHEMBL9608334 | 0.66 | PDE1B (0.52) | PDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353556-A1 | ORGANIC COMPOUNDS | CYP2C9, TPMT, CYP2C19 | PRKDC 3085/4885PIK3CA 288/4885MTOR 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.